| Literature DB >> 36193520 |
Adeola Anike Oni1, Stephen Olufemi Babalola2, Adeyeri David Adeleye1, Temidayo Ebenezer Olagunju2, Ijeoma Anthonia Amama1, Esther Onaopemipo Omole1, Ezra Ajibola Adegboye1, Obokparo Godspower Ohore3.
Abstract
Unserviceable vehicles imported from developed countries are often dismantled in automobile junk markets and the useable parts sold. This generates hazardous waste oils which contain contaminants detrimental to the environment and human health. In this study, we quantified the potential human health risks associated with oral and dermal exposure to heavy metals and PAHs in well-water samples from a major automobile junk market in Ibadan, SW-Nigeria. Twenty-four to thirty-one water samples from seven wells within the market were analyzed for seven metals and eight PAHs using standard methods. Hazard-Quotient (HQ), Hazard-Index (HI), and Carcinogenic-Risk (CR) were computed for children and adults based on the USEPA Human-Health Risk Assessment model. Iron, Lead, Arsenic, Cadmium, Benzo(a)Anthracene, and Benzo(a)Pyrene exceeded regulatory limits. In children and adults, lead (1.14-3.71), cadmium (1.26-2.60) and arsenic (1.03-4.33) had HQingestion values exceeding 1. In addition, cadmium also posed risks via the dermal route in children in two of the seven sampled wells with an HQ of 1.76. Hazard Index was >1 via both routes in children (HIingestion:- 5.04-10.07; HIdermal:- 1.12-2.12) but only via ingestion in adults (HI ingestion:- 2.36-4.85). Well-3 samples posed the greatest non-carcinogenic risks via ingestion with HI values of 10.07 (children) and 4.85 (adults) respectively. Cadmium, arsenic, lead, and chromium could also elicit carcinogenic risk, with CR values of 1.00E - 02, 1.95E - 03, 1.11E - 04, and 3.30E - 04 which exceeded the 10-4 limit indicating high risk, particularly in children. However, HQ and HI values for PAHs were <1 via both pathways suggesting no non-carcinogenic risk from PAH exposure. Carcinogenic risk estimates for Benzo(a)Anthracene (9.66E - 04) and Benzo(a)Pyrene (2.31E - 04) suggest moderate risks in exposed children via the dermal route. Adverse health effects including cancer may occur in the exposed population on prolonged usage of these polluted water sources. Urgent remediation measures are therefore necessary to protect the exposed population.Entities:
Keywords: Araromi; Automobile scrap; Cancer risk; Groundwater; Hazard index; Hazard quotient; Ibadan
Year: 2022 PMID: 36193520 PMCID: PMC9526163 DOI: 10.1016/j.heliyon.2022.e10688
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Figure 1Map of Ibadan North-East LGA, Oyo state, Nigeria showing the Araromi spare-parts market with the study wells 1-7 highlighted.
Figure 2(a-d) Mean percentage distribution of Araromi population by (a) sex (b) age (c) number of years living or working at the market (d) residential status.
Figure 3Mean percentage distribution of Araromi population by occupation.
Figure 4Water usage pattern of Araromi population (a) frequency of usage (b) purpose of water use.
Average Daily Dose (ADD) for both oral and dermal exposure to heavy metals in the seven wells.
| METALS | Well 1 | Well 2 | Well 3 | Well 4 | Well 5 | Well 6 | Well 7 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | |
| 1.9E – 1 | 1.26E – 3 | 1.5E – 1 | 9.94E – 4 | 1.0E – 1 | 6.78E – 4 | 1.4E – 1 | 9.20E – 4 | 6.1E – 2 | 4.05E – 4 | 8.8E – 2 | 5.81E – 4 | 5.1E – 2 | 3.34E – 4 | |
| 4.6E – 3 | 3.08E – 5 | 3.3E – 3 | 2.20E – 5 | 2.6E – 3 | 1.76E – 5 | 6.0E – 3 | 3.96E – 5 | 4.0E – 3 | 2.64E – 5 | 2.6E – 3 | 1.76E – 5 | 2.7E – 3 | 1.76E – 5 | |
| 1.3E – 2 | 8.36E – 5 | 1.3E – 2 | 8.80E – 5 | 9.3E – 3 | 6.16E – 5 | 6.0E – 3 | 3.96E – 5 | 6.6E – 3 | 4.40E – 5 | 6.7E – 3 | 4.40E – 5 | 4.0E – 3 | 2.64E – 5 | |
| 6.6E – 4 | 8.80E – 6 | 6.6E – 4 | 8.80E – 6 | 6.6E – 4 | 8.80E – 6 | 6.6E – 4 | 8.80E – 6 | 6.6E – 4 | 8.80E – 6 | 6.6E – 4 | 8.80E – 6 | 6.6E – 4 | 8.80E – 6 | |
| 6.7E – 4 | 4.40E – 6 | 1.3E – 3 | 8.80E – 6 | 1.3E – 3 | 8.80E – 6 | 6.6E – 4 | 4.40E – 6 | 6.7E – 4 | 4.40E – 6 | 6.6E – 4 | 4.40E – 6 | 6.6E – 4 | 4.40E – 6 | |
| 2.6E – 3 | 1.06E – 5 | 4.7E – 3 | 1.85E – 5 | 1.5E – 2 | 5.81E – 5 | 1.8E – 2 | 7.13E – 5 | 6.0E – 3 | 2.38E – 5 | 6.6E – 3 | 2.64E – 5 | 4.7E – 3 | 1.85E – 5 | |
| 6.6E – 4 | 4.40E – 6 | 6.6E – 4 | 4.40E – 6 | 1.3E – 3 | 8.80E – 6 | 1.3E – 3 | 8.80E – 6 | 1.3E – 3 | 8.80E – 6 | 6.6E – 4 | 4.40E – 6 | 6.6E – 4 | 4.40E – 6 | |
| 9.0E – 2 | 4.28E – 4 | 7.1E – 2 | 3.37E – 4 | 4.8E – 2 | 2.30E – 4 | 6.6E – 2 | 3.12E – 4 | 2.9E – 2 | 1.37E – 4 | 4.1E – 2 | 1.97E – 4 | 2.4E – 2 | 1.13E – 4 | |
| 2.2E – 3 | 1.04E – 5 | 1.6E – 3 | 7.46E – 6 | 1.3E – 3 | 5.97E – 6 | 2.8E – 3 | 1.34E – 5 | 1.9E – 3 | 8.95E – 6 | 1.3E – 3 | 5.97E – 6 | 1.3E – 3 | 5.97E – 6 | |
| 6.0E – 3 | 2.83E – 5 | 6.3E – 3 | 2.98E – 5 | 4.4E – 3 | 2.09E – 5 | 2.8E – 3 | 1.34E – 5 | 3.1E – 3 | 1.49E – 5 | 3.1E – 3 | 1.49E – 5 | 1.9E – 3 | 8.95E – 6 | |
| 3.1E – 4 | 2.98E – 6 | 3.1E – 4 | 2.98E – 6 | 3.1E – 4 | 2.98E – 6 | 3.1E – 4 | 2.98E – 6 | 3.1E – 4 | 2.98E – 6 | 3.1E – 4 | 2.98E – 6 | 3.1E – 4 | 2.98E – 6 | |
| 3.1E – 4 | 1.49E – 6 | 6.3E – 4 | 2.98E – 6 | 6.3E – 4 | 2.98E – 6 | 3.1E – 4 | 1.49E – 6 | 3.1E – 4 | 1.49E – 6 | 3.1E – 4 | 1.49E – 6 | 3.1E – 4 | 1.49E – 6 | |
| 1.3E – 3 | 3.58E – 6 | 2.2E – 3 | 6.26E – 6 | 6.9E – 3 | 1.97E – 5 | 8.5E – 3 | 2.42E – 5 | 2.8E – 3 | 8.05E – 6 | 3.1E – 3 | 8.94E – 6 | 2.2E – 3 | 6.26E – 6 | |
| 3.1E – 4 | 1.49E – 6 | 3.1E – 4 | 1.49E – 6 | 6.3E – 4 | 2.98E – 6 | 6.3E – 4 | 2.98E – 6 | 6.3E – 4 | 2.98E – 6 | 3.1E – 4 | 1.49E – 6 | 3.1E – 4 | 1.49E – 6 | |
Average Daily Dose (ADD) for both Oral and Dermal exposure to PAHs in the seven wells.
| PAHs | Control | Well 1 | Well 2 | Well 3 | Well 4 | Well 5 | Well 6 | Well 7 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | |
| Anthracene | 6.67E – 8 | NA | 3.33E – 6 | NA | 2.00E – 6 | NA | 2.00E – 6 | NA | 1.33E – 6 | NA | 6.67E – 7 | NA | 6.67E – 7 | NA | 3.33E – 6 | NA |
| Fluoranthene | 0.00E00 | 0.00E00 | 1.33E – 6 | 3.17E – 6 | 6.67E – 7 | 1.58E – 6 | 6.67E – 7 | 1.58E – 6 | 2.67E – 7 | 6.34E – 7 | 2.0E – 7 | 4.75E – 7 | 4.67E – 7 | 1.11E – 6 | 1.33E – 6 | 3.17E – 6 |
| Pyrene | 0.00E00 | NA | 1.80E – 5 | NA | 1.33E – 5 | NA | 2.07E – 5 | NA | 9.33E – 6 | NA | 4.00E – 6 | NA | 8.00E – 6 | NA | 2.00E – 5 | NA |
| Benzo(a)anthracene | 6.67E – 7 | 3.56E – 6 | 4.27E – 5 | 2.28E – 4 | 3.27E – 5 | 1.75E – 4 | 3.73E – 5 | 2.00E – 4 | 2.80E – 5 | 1.50E – 4 | 2.07E – 5 | 1.11E – 4 | 3.00E – 5 | 1.60E – 4 | 4.13E – 5 | 2.21E – 4 |
| Chrysene | 0.00E00 | 0 .00E00 | 1.33E – 6 | 7.13E – 6 | 4.00E – 7 | 2.14E – 6 | 1.33E – 6 | 7.13E – 6 | 4.00E – 7 | 2.14E – 6 | 2.67E – 7 | 1.43E – 6 | 2.67E – 7 | 1.43E – 6 | 6.67E – 7 | 3.56E – 6 |
| Benzo(b)fluoranthene | 6.67E – 8 | 5.28E – 7 | 2.00E – 6 | 1.58E – 5 | 2.67E – 6 | 7.16E – 6 | 1.33E – 6 | 1.06E – 5 | 6.67E – 7 | 5.28E – 6 | 2.00E – 7 | 1.58E – 6 | 2.67E – 7 | 2.11E – 6 | 3.33E – 6 | 2.64E – 5 |
| Benzo(a)pyrene | 0.00E00 | 0.00E00 | 4.00E – 6 | 3.17E – 5 | 2.67E – 6 | 2.11E – 5 | 3.33E – 6 | 2.64E – 5 | 2.00E – 6 | 1.58E – 5 | 6.67E – 7 | 5.28E – 6 | 1.33E – 6 | 1.06E – 5 | 3.33E – 6 | 2.64E – 5 |
| Benzo-1,2-anthracene | 2.00E – 7 | NA | 2.53E – 5 | NA | 1.87E – 5 | NA | 2.13E – 5 | NA | 1.13E – 5 | NA | 5.33E – 6 | NA | 1.00E – 5 | NA | 2.80E – 5 | NA |
| Anthracene | 3.14E – 8 | NA | 1.57E – 6 | NA | 9.43E – 7 | NA | 9.43E – 7 | NA | 6.29E – 7 | NA | 3.14E – 7 | NA | 3.14E – 7 | NA | 1.57E – 6 | NA |
| Fluoranthene | 0.00E00 | 0.00E00 | 6.29E – 7 | 1.07E – 6 | 3.14E – 7 | 5.37E – 7 | 3.14E – 7 | 5.37E – 7 | 1.26E – 7 | 2.15E – 7 | 9.43E – 8 | 1.61E – 7 | 2.20E – 7 | 3.76E – 7 | 6.29E – 7 | 1.07E – 6 |
| Pyrene | 0.00E00 | NA | 8.49E – 6 | NA | 6.29E – 6 | NA | 9.74E – 6 | NA | 4.40E – 6 | NA | 1.89E – 6 | NA | 3.77E – 6 | NA | 9.43E – 6 | NA |
| Benzo(a)anthracene | 3.14E – 7 | 1.21E – 6 | 2.01E – 5 | 7.73E – 5 | 1.54E – 5 | 5.92E – 5 | 1.76E – 5 | 6.77E – 5 | 1.32E – 5 | 5.07E – 5 | 9.74E – 6 | 3.74E – 5 | 1.41E – 5 | 5.44E – 5 | 1.95E – 5 | 7.49E – 5 |
| Chrysene | 0.00E00 | 0 .00E00 | 6.29E – 7 | 2.42E – 6 | 1.89E – 7 | 7.25E – 7 | 6.29E – 7 | 2.42E – 6 | 1.89E – 7 | 7.25E – 7 | 1.26E – 7 | 4.83E – 7 | 1.26E – 7 | 4.83E – 7 | 3.14E – 7 | 1.21E – 6 |
| Benzo(b)fluoranthene | 3.14E – 8 | 1.79E – 7 | 9.43E – 7 | 5.37E – 6 | 1.26E – 6 | 7.16E – 6 | 6.29E – 7 | 3.58E – 6 | 3.14E – 7 | 1.79E – 6 | 9.43E – 8 | 5.37E – 7 | 1.26E – 7 | 7.16E – 7 | 1.57E – 6 | 8.95E – 6 |
| Benzo(a)pyrene | 0.00E00 | 0.00E00 | 1.89E – 6 | 1.07E – 5 | 1.26E – 6 | 7.16E – 6 | 1.57E – 6 | 8.95E – 6 | 9.43E – 7 | 5.37E – 6 | 3.14E – 7 | 1.79E – 6 | 6.29E – 7 | 3.58E – 6 | 1.57E – 6 | 8.95E – 6 |
| Benzo-1,2-anthracene | 9.43E – 7 | NA | 1.19E – 5 | NA | 8.80E – 6 | NA | 1.01E – 5 | NA | 5.34E – 6 | NA | 2.51E – 6 | NA | 4.71E – 6 | NA | 1.32E – 5 | NA |
Hazard Quotient (HQ) for both oral and dermal exposure to heavy metals in the seven wells.
| METALS | Well 1 | Well 2 | Well 3 | Well 4 | Well 5 | Well 6 | Well 7 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | |
| 2.71E – 1 | 9.00E – 3 | 2.14E – 1 | 7.10E – 3 | 1.43E – 1 | 4.84E – 3 | 2.00E – 1 | 6.57E – 3 | 8.71E – 2 | 2.89E – 3 | 1.26E – 1 | 4.15E – 3 | 7.29E – 2 | 2.39E – 3 | |
| 1.15E – 1 | 2.57E – 3 | 8.25E – 1 | 1.83E – 3 | 6.50E – 2 | 1.47E – 3 | 1.50E – 1 | 3.30E – 3 | 1.00E – 1 | 2.20E – 3 | 6.50E – 2 | 1.47E – 3 | 6.75E – 2 | 1.47E – 3 | |
| 1.66E – 1 | 1.66E – 1 | 1.16E – 1 | 7.47E – 2 | 8.30E – 2 | 8.30E – 2 | 4.98E – 2 | ||||||||
| 2.20E – 1 | 1.47E – 1 | 2.20E – 1 | 1.47E – 1 | 2.20E – 1 | 1.47E – 1 | 2.20E – 1 | 1.47E – 1 | 2.20E – 1 | 1.47E – 1 | 2.20E – 1 | 1.47E – 1 | 2.20E – 1 | 1.47E – 1 | |
| 8.80E – 1 | 8.80E – 1 | 8.80E – 1 | 8.80E – 1 | 8.80E – 1 | ||||||||||
| 8.67E – 3 | 1.77E – 4 | 1.53E – 2 | 3.08E – 4 | 4.90E – 2 | 9.68E – 4 | 6.00E – 2 | 1.19E – 3 | 2.00E – 2 | 3.97E – 4 | 2.20E – 2 | 4.40E – 4 | 1.53E – 2 | 3.08E – 4 | |
| 3.58E – 2 | 3.58E – 2 | 7.15E – 2 | 7.15E – 2 | 7.15E – 2 | 3.58E – 2 | 3.58E – 2 | ||||||||
| 1.3E – 1 | 3.06E – 3 | 1.0E – 1 | 2.41E – 3 | 7.0E – 2 | 1.64E – 3 | 9.0E – 2 | 2.23E – 3 | 4.1E – 2 | 9.79E – 4 | 5.9E – 2 | 1.41E – 3 | 3.4E – 2 | 8.07E – 4 | |
| 5.5E – 2 | 8.67E – 4 | 3.9E – 2 | 6.21E – 4 | 3.3E – 2 | 4.98E – 4 | 7.0E – 2 | 1.12E – 3 | 4.8E – 2 | 7.46E – 4 | 3.3E – 2 | 4.98E – 4 | 3.3E – 2 | 4.98E – 4 | |
| 5.69E – 2 | 5.69E – 2 | 3.99E – 2 | 8.0E – 1 | 2.56E – 2 | 8.9E – 1 | 2.84E – 2 | 9.0E – 1 | 2.80E – 2 | 5.4E – 1 | 1.71E – 2 | ||||
| 1.0E – 1 | 4.97E – 2 | 1.0E – 1 | 4.97E – 2 | 1.0E – 1 | 4.97E – 2 | 1.0E – 1 | 4.97E – 2 | 1.0E – 1 | 4.97E – 2 | 1.0E – 1 | 4.97E – 2 | 1.0E – 1 | 4.97E – 2 | |
| 6.2E – 1 | 2.98E – 1 | 5.96E – 1 | 5.96E – 1 | 6.2E – 1 | 2.98E – 1 | 6.3E – 1 | 2.98E – 1 | 6.2E – 1 | 2.98E – 1 | 6.2E – 1 | 2.98E – 1 | |||
| 4.33E – 3 | 5.97E – 5 | 7.33E – 3 | 1.04E – 4 | 2.30E – 2 | 3.28E – 4 | 2.83E – 2 | 4.03E – 4 | 9.3E – 3 | 1.34E – 4 | 1.03E – 2 | 1.49E – 4 | 7.33E – 3 | 1.04E – 4 | |
| 1.21E – 2 | 1.21E – 2 | 2.42E – 2 | 2.42E – 2 | 2.42E – 2 | 1.21E – 2 | 1.21E – 2 | ||||||||
| 4.20E – 1 | 7.18E – 1 | 7.12E – 1 | 4.01E – 1 | 4.02E – 1 | 3.84E – 1 | 3.78E – 1 | ||||||||
a Values in bold and underlined exceed unity. Exposure to these would elicit non-carcinogenic health risks.
Hazard Quotient (HQ) for both oral and dermal exposure to PAHs in the seven wells.
| PAHs | Control | Well 1 | Well 2 | Well 3 | Well 4 | Well 5 | Well 6 | Well 7 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | |
| 2.22E – 7 | 1.11E – 5 | 6.66E – 6 | 6.66E – 6 | 4.43E – 6 | 2.22E – 6 | 2.22E – 6 | 1.11E – 5 | |||||||||
| 0.00E00 | 0.0E00 | 3.33E – 5 | 7.93E – 5 | 1.67E – 5 | 3.95E – 5 | 1.67E – 5 | 3.95E – 5 | 6.68E – 6 | 1.59E – 5 | 5.00E – 6 | 1.19E – 5 | 1.17E – 5 | 2.78E – 5 | 3.33E – 5 | 7.93E – 5 | |
| 0.00E00 | 6.00E – 4 | 4.43E – 4 | 6.90E – 4 | 3.11E – 4 | 1.33E – 4 | 2.66E – 4 | 6.66E – 4 | |||||||||
| 0.00E00 | 0.0E00 | 1.33E – 2 | 1.06E – 1 | 8.90E – 3 | 7.03E – 2 | 1.11E – 2 | 8.80E – 2 | 6.66E – 3 | 5.26E – 2 | 2.22E – 3 | 1.76E – 2 | 4.43E – 3 | 3.53E – 2 | 1.11E – 2 | 8.80E – 2 | |
| 1.05E – 7 | 5.23E – 6 | 3.14E – 6 | 3.14E – 6 | 2.10E – 6 | 1.05E – 6 | 1.05E – 6 | 5.23E – 6 | |||||||||
| 0.00E00 | 0.0E00 | 1.57E – 5 | 2.68E – 5 | 7.85E – 6 | 1.34E – 5 | 7.85E – 6 | 1.34E – 5 | 3.15E – 6 | 5.38E – 6 | 2.36E – 6 | 4.03E – 6 | 5.50E – 6 | 9.40E – 6 | 1.57E – 5 | 2.68E – 5 | |
| 0.00E00 | 2.83E – 4 | 2.10E – 4 | 3.25E – 4 | 1.47E – 4 | 6.3E – 5 | 1.26E – 4 | 3.14E – 4 | |||||||||
| 0.00E00 | 0.0E00 | 6.3E – 3 | 3.57E – 2 | 4.2E – 3 | 2.39E – 2 | 5.23E – 4 | 2.98E – 2 | 3.14E – 3 | 1.79E – 2 | 1.05E – 3 | 5.97E – 3 | 2.10E – 3 | 1.19E – 2 | 5.23E – 3 | 2.98E – 2 | |
Cancer Risk (CR) for both oral and dermal exposure to heavy metals in the seven wells.
| METALS | Well 1 | Well 2 | Well 3 | Well 4 | Well 5 | Well 6 | Well 7 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | |
| 7.91E – 5 | 9.24E – 5 | 5.10E – 5 | 5.94E – 5 | 5.61E – 5 | 6.60E – 5 | 4.51E – 5 | 5.28E – 5 | 3.40E – 5 | 3.96E – 5 | |||||
| - | ||||||||||||||
| 1.61E – 5 | 1.61E – 5 | 3.22E – 5 | 3.22E – 5 | 3.22E – 5 | 1.61E – 5 | 1.61E – 5 | ||||||||
| 5.36E – 5 | 4.47E – 5 | 5.36E – 5 | 4.47E – 5 | 3.74E – 5 | 3.13E – 5 | 2.38E – 5 | 2.01E – 5 | 2.64E – 5 | 2.24E – 5 | 2.13E – 5 | 1.79E – 5 | 1.62E – 5 | 1.34E – 5 | |
| 5.96E – 5 | 5.96E – 5 | 5.96E – 5 | 5.96E – 5 | 5.96E – 5 | 5.96E – 5 | 5.96E – 5 | ||||||||
| - | - | - | - | - | - | - | ||||||||
| 5.45E – 6 | 5.45E – 6 | 1.09E – 5 | 1.09E – 5 | 1.09E – 5 | 5.45E – 6 | 5.45E – 6 | ||||||||
a Italicized values are indicative of moderate cancer risk. Italicized, emboldened and underlined values indicate high cancer risk. Values in normal font are indicative of low cancer risk.
Cancer Risk for Oral and Dermal Exposure to PAHs in the seven wells.
| PAHs | Control | Well 1 | Well 2 | Well 3 | Well 4 | Well 5 | Well 6 | Well 7 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | Oral | Dermal | |
| 4.87E – 7 | 2.60E – 6 | 3.12E – 5 | 2.39E – 5 | 2.72E – 5 | 2.04E – 5 | 1.51E – 5 | 8.10E – 5 | 2.19E – 5 | 3.01E – 5 | |||||||
| 0.00E0 | 0.00E0 | 9.71E – 9 | 5.20E – 8 | 2.92E – 9 | 1.56E – 8 | 9.71E – 9 | 5.20E – 8 | 2.92E – 9 | 1.56E – 8 | 1.95E – 9 | 1.04E – 8 | 1.95E – 9 | 1.04E – 8 | 4.87E – 9 | 2.60E – 8 | |
| 4.87E – 8 | 3.85E – 7 | 1.46E – 6 | 1.15E – 5 | 1.95E – 6 | 5.23E – 6 | 9.71E – 7 | 7.74E – 6 | 4.87E – 7 | 3.85E – 6 | 1.46E – 7 | 1.15E – 6 | 1.95E – 7 | 1.54E – 6 | 2.43E – 6 | 1.93E – 5 | |
| 0.00E0 | 0.00E0 | 4.38E – 5 | 1.95E – 5 | 2.43E – 5 | 1.46E – 5 | 4.87E – 6 | 3.85E – 5 | 9.71E – 6 | 7.74E – 5 | 2.43E – 5 | ||||||
| 2.29E – 7 | 8.83E – 7 | 1.47E – 5 | 5.64E – 5 | 1.12E – 5 | 4.32E – 5 | 1.28E – 5 | 4.94E – 5 | 9.64E – 6 | 3.70E – 5 | 7.11E – 6 | 2.74E – 5 | 1.03E – 5 | 3.97E – 5 | 1.42E – 5 | 5.47E – 5 | |
| 0.00E0 | 0.00E0 | 4.59E – 9 | 1.77E – 8 | 1.38E – 9 | 5.29E – 9 | 4.59E – 9 | 1.77E – 8 | 1.38E – 9 | 5.29E – 9 | 9.20E – 10 | 3.92E – 9 | 9.2E – 10 | 5.23E – 9 | 2.29E – 9 | 6.53E – 8 | |
| 2.29E – 8 | 1.30E – 7 | 6.88E – 7 | 3.92E – 6 | 9.20E – 7 | 5.23E – 6 | 4.59E – 7 | 2.61E – 6 | 2.29E – 7 | 1.31E – 6 | 6.88E – 8 | 3.92E – 7 | 9.19E – 8 | 5.23E – 7 | 1.15E – 6 | 6.53E – 6 | |
| 0.00E0 | 0.00E0 | 1.38E – 5 | 7.81E – 5 | 9.20E – 6 | 5.23E – 5 | 1.15E – 6 | 6.53E – 5 | 6.88E – 6 | 3.92E – 5 | 2.29E – 6 | 1.31E – 5 | 4.59E – 6 | 2.61E – 5 | 1.15E – 5 | 6.53E – 5 | |
a Italicized values are indicative of moderate cancer risk, while those in normal font are indicative of very low to low cancer risk.
Range (in brackets), and mean concentration of heavy metals in control and well-water samples (mg/L).
| Samples | Fe (mg/L) | Cu (mg/L) | Pb (mg/L) | Cr (mg/L) |
|---|---|---|---|---|
| Control | 0.00 ± 0.00a | 0.00 ± 0.00a | 0.00 ± 0.00a | 0.00 ± 0.00a |
| Well 1 | (0.058–0.09); 0.07 | (0.00–0.03); 0.01 | ||
| Well 2 | (0.03–0.07); 0.05 | (0.00–0.03); 0.01 | ||
| Well 3 | (0.03–0.05); 0.04 | (0.001– | (0.00–0.02); 0.01 | |
| Well 4 | (0.04–0.12); 0.09 | (0.003– | (0.00–0.02); 0.01 | |
| Well 5 | (0.00–0.11); 0.06 | (0.0007– | (0.00–0.02); 0.01 | |
| Well 6 | (0.00–0.11); 0.04 | (0.00– | (0.00–0.01); 0.01 | |
| Well 7 | (0.00–0.11); 0.04 | (0.00 | (0.00–0.02); 0.01 | |
| USEPA (2009) |
∗: Statistically significant = P ≤ 0.05. Values are mean ± S.D, Superscripts differ significantly (P < 0.05) from Duncan post hoc test analysis and means with the same letter across the groups are not significantly different from each other. Italicized values exceeded one or more drinking water regulatory standards.
Range (in brackets), and mean concentration of heavy metals in control and well-water samples (mg/L).
| Samples | Cd (mg/L) | Zn (mg/L) | As (mg/L) |
|---|---|---|---|
| Control | 0.00 ± 0.00a | 0.00 ± 0.00a | (0.00– |
| Well 1 | (0.00–0.12); 0.04 | (0.00– | |
| Well 2 | (0.00–0.1); 0.07 | (0.00– | |
| Well 3 | (0.12–0.29); 0.22 | (0.00– | |
| Well 4 | (0.16–0.34); 0.27 | (0.00– | |
| Well 5 | (0.00–0.29); 0.09 | (0.00– | |
| Well 6 | (0.06–0.13); 0.10 | (0.00– | |
| Well 7 | (0.009–0.17); 0.07 | (0.00– | |
| USEPA (2009) |
∗: Statistically significant = P ≤ 0.05. Values are mean ± S.D, Superscripts differ significantly (P < 0.05) from Duncan post hoc test analysis and means with the same letter across the groups are not significantly different from each other. Italicized values exceeded one or more drinking water regulatory standards.
Cd=Cadmium; Zn = Zinc; As=Arsenic.
Range and mean concentrations of Polycyclic Aromatic Hydrocarbon (PAHs) in Control and Well-water samples (μg/L).
| Samples | ANT | FLT | PYR | BaA |
|---|---|---|---|---|
| Control | (0.001–0.002) 0.001 ± 0.00a | (0.00–0.00) 0.00 ± 0.00a | (0.00–0.00) 0.00 ± 0.00a | (0.011–0.014) 0.01 ± 0.00a |
| Well 1 | (0.044–0.062) 0.05 ± 0.01c | (0.013–0.023) 0.02 ± 0.006ab | (0.019–0.425) 0.27 ± 0.22bc | |
| Well 2 | (0.0255–0.026) 0.03 ± 0.00abc | (0.009–0.012) 0.01 ± 0.002ab | (0.150–0.240) 0.20 ± 0.05abc | |
| Well 3 | (0.028–0.045) 0.03 ± 0.01bc | (0.01–0.014) 0.01 ± 0.002b | (0.164–0.415) 0.31 ± 0.13c | |
| Well 4 | (0.0015–0.039) 0.02 ± 0.02abc | (0.00–0.008) 0.004 ± 0.003a | (0.011–0.215) 0.14 ± 0.09abc | |
| Well 5 | (0.0005–0.021) 0.01 ± 0.01ab | (0.00–0.006) 0.003 ± 0.002ab | (0.009–0.120) 0.06 ± 0.05ab | |
| Well 6 | (0.0085–0.025) 0.01 ± 0.01ab | (0.004–0.012) 0.007 ± 0.004ab | (0.095–0.140) 0.12 ± 0.02abc | |
| Well 7 | (0.00–0.091) 0.05 ± 0.04c | (0.00–0.031) 0.02 ± 0.01ab | (0.005–0.535) 0.30 ± 0.22c | |
| - | - | - | - | |
| - | - | - | ||
| - | - | - | - | |
| 0.18 |
∗: Statistically significant = P ≤ 0.05 Values are mean ± S.D, Superscripts differ significantly (P < 0.05) from Duncan post hoc test analysis and means with the same letter across the groups are not significantly different from each other. Except for the International and National Environmental Quality Standards for Substances in the Netherlands (INS, 2011), which stated a regulatory limit for benzo (a) anthracene, all other regulatory limits given were for benzo (a) pyrene while SON limits were not specific with respect to a particular PAH. Italicized figures exceeded one or more drinking water regulatory standards.
Ant = Anthracene; Flt = Fluoranthene; Pyr =Pyrene; BaA =Benzo(a)Anthracene.
Range and mean concentrations of Polycyclic Aromatic Hydrocarbon (PAHs) in Control and Well-water samples (μg/L).
| Samples | CHR | BbF | BaP | B-1,2A |
|---|---|---|---|---|
| Control | (0.00–0.00) 0.00 ± 0.00a | (0.001–0.002) 0.001 ± 0.00a | (0.00–0.00) 0.00 ± 0.00a | (0.002–0.005) 0.003 ± 0.002a |
| Well 1 | (0.004–0.019) 0.01 ± 0.008c | (0.022–0.046) 0.03 ± 0.01ab | (0.33–0.465) 0.38 ± 0.08c | |
| Well 2 | (0.003–0.009) 0.006 ± 0.003abc | (0.012–0.057) 0.04 ± 0.03b | (0.233–0.310) 0.28 ± 0.04bc | |
| Well 3 | (0.006–0.017) 0.01 ± 0.006bc | (0.01–0.025) 0.02 ± 0.009ab | (0.26–0.394) 0.32 ± 0.07bc | |
| Well 4 | (0.004–0.01) 0.006 ± 0.003abc | (0.00–0.017) 0.01 ± 0.007ab | (0.016–0.317) 0.17 ± 0.13ab | |
| Well 5 | (0.0015–0.006) 0.004 ± 0.002ab | (0.00–0.004) 0.003 ± 0.002a | (0.00–0.016) 0.01 ± 0.007a | (0.001–0.11) 0.08 ± 0.05ab |
| Well 6 | (0.003–0.004) 0.004 ± 0.001ab | (0.002–0.009) 0.004 ± 0.004a | (0.126–0.170) 0.15 ± 0.02ab | |
| Well 7 | (0.001–0.01) 0.01 ± 0.01abc | (0.00–0.082) 0.05 ± 0.04ab | (0.002–0.638) 0.42 ± 0.29c | |
| - | - | 0.7; 0.7 | ||
| - | - | 0.01 | ||
| - | - | 0.2 | ||
∗: Statistically significant = P ≤ 0.05 Values are mean ± S.D, Superscripts differ significantly (P < 0.05) from Duncan post hoc test analysis and means with the same letter across the groups are not significantly different from each other. Except for the International and National Environmental Quality Standards for Substances in the Netherlands (INS, 2011), which stated a regulatory limit for benzo (a) anthracene, all other regulatory limits given were for benzo (a) pyrene while SON limits were not specific with respect to a particular PAH. Italicized figures exceeded one or more drinking water regulatory standards.
Chr = Chrysene; BbF = Benzo(b)Fluoranthene; BaP = Benzo(a)Pyrene; B-1,2A = Benzo 1, 2-Anthracene.